The need to develop acceptable, available point-of-care tests (POCT) for diagnosing sexually transmitted diseases (STDs) for all at-risk populations is significant. Five of the top ten reportable diseases in the United States are STDs. There are over 15 million new STDs per year. Costs to the U.S. for STDs are over $2 billion per year. Stigma, privacy, and confidentiality issues make STDs optimal areas for point-of-care tests at healthcare facilities and for over-the-counter (OTC) assays performed at home.